title: Sebaceous hyperplasia: systemic treatment with isotretinoin.
abstract: The study aimed to verify the therapeutic action of isotretinoin in the treatment of sebaceous hyperplasia. During two months, 20 patients with sebaceous hyperplasia took isotretinoin at a dosage of 1mg/kg per day. Their skin lesions were counted and photographed before and after treatment and re-evaluated two years later. The average number of sebaceous hyperplasia lesions before treatment was 24 per patient. At the end of two months of therapy, the number of lesions decreased to 2 per patient. The statistically analyzed data showed a reduction in the number of lesions following isotretinoin use (p < 0.05). Two years after the end of the treatment, the average number of sebaceous hyperplasia lesions was 4 per patient. There were no severe side effects. Thus, the data analysis suggests that isotretinoin is a safe and effective drug for treating the disease under study.
authors.affiliation: Campinas, Campinas, SP, Brazil.
authors.forename: Sandra
authors.initials: S
authors.lastname: Tagliolatto
authors.affiliation: Universidade Estadual de Campinas, Campinas, SP, Brazil.
authors.forename: Octavio de Oliveira
authors.initials: Ode O
authors.lastname: Santos Neto
authors.affiliation: Universidade Federal de São Paulo, São Paulo, SP, Brazil.
authors.forename: Maurício Mota de Avelar
authors.initials: MM
authors.lastname: Alchorne
authors.affiliation: Universidade Federal de São Paulo, São Paulo, SP, Brazil.
authors.forename: Mauro Yoshiaki
authors.initials: MY
authors.lastname: Enokihara
mesh_terms: D000328:Adult; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy; D015474:Isotretinoin / Q000627:therapeutic use*; D012625:Sebaceous Gland Diseases / Q000188:drug therapy*; D012627:Sebaceous Glands / Q000473:pathology*; D012867:Skin / Q000187:drug effects; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D015474:Isotretinoin
references.citation: J Invest Dermatol. 2005 Oct;125(4):673-84
references.pmid: 16185265
references.citation: Pediatr Dermatol. 2005 Jul-Aug;22(4):357-9
references.pmid: 16060877
references.citation: Arch Iran Med. 2006 Jul;9(3):228-30
references.pmid: 16859056
references.citation: J Invest Dermatol. 2006 Sep;126(9):2002-9
references.pmid: 16675962
references.citation: J Clin Invest. 2008 Apr;118(4):1468-78
references.pmid: 18317594
references.citation: J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):127-8
references.pmid: 10607331
references.citation: Dermatol Surg. 2000 Jul;26(7):649-52
references.pmid: 10886272
references.citation: Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15
references.pmid: 11586072
references.citation: J Am Acad Dermatol. 2001 Nov;45(5):S143-9
references.pmid: 11606946
references.citation: J Am Acad Dermatol. 2002 Apr;46(4):505-9
references.pmid: 11907498
references.citation: Skin Therapy Lett. 2004 Mar;9(3):1-4
references.pmid: 15037925
references.citation: Cutis. 1984 Jul;34(1):90-2
references.pmid: 6590206
references.citation: Dermatology. 1996;193(2):127-30
references.pmid: 8884149
references.citation: Dermatology. 1997;195 Suppl 1:1-3; discussion 38-40
references.pmid: 9310738
references.citation: Dermatology. 1997;195 Suppl 1:22-8; discussion 38-40
references.pmid: 9310742
references.citation: Dermatology. 1998;196(1):21-31
references.pmid: 9557220
references.citation: Dermatology. 1998;196(1):140-7
references.pmid: 9557249
references.citation: Lasers Surg Med. 1999;25(1):8-12
references.pmid: 10421881
references.citation: J Drugs Dermatol. 2004 Nov-Dec;3(6 Suppl):S6-9
references.pmid: 15624735
references.citation: J Am Acad Dermatol. 2006 Apr;54(4):644-6
references.pmid: 16546586